Gradalis® Presents Initial Data from Phase II U.S. Trial for Ewing’s sarcoma at the Annual Meeting of the Children’s Oncology Group
November 09, 2018 10:04 ET | Gradalis, Inc.
DALLAS, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Gradalis, Inc., a clinical-stage immunotherapy company developing investigational treatments for individuals suffering from multiple cancer indications,...
Gradalis® Announces Initiation of Phase 3 Study of Vigil™ in Ewing’s sarcoma
August 28, 2018 19:16 ET | Gradalis, Inc.
– The open-label trial will measure progression free survival of participants from date of randomization until first disease progression in the study – – The trial will use product produced from...